Citations

Clear

25 citation(s) found for "Chen, Chao".

Early graft failure after adult living donor liver transplantation: A multicenter risk analysis and development of the early allograft failure in living donor liver transplantation (EAGLE-LDLT) model
Li, Zhihao, Centonze, Leonardo , Raptis, Dimitri , Marquez, Kris Ann Hervera , Rammohan, Ashwin, Gunasekaran, Vasanthakumar , Hong, Suyoung , Chen, I Lun, KIM, Jongman , Hsu, Shih-Chao , Akamatsu, Nobuhisa, Shaked, Oren, Genedy, Lara, Dutkowski, Philipp , Nadalin, Silvio, Boehnert, Markus U, Mathur, Abhishek, Emond, J., Testa, Giuliano, Olthoff, Kim, Taner, Timucin, Wong, Tiffany CL, Hasegawa, Kiyoshi, Balci, D., Cattral, Mark, Sapisochin, G., Selzner, Nazia, Jeng, Long-Bin, Chen, Chao-Long, Suh, Kyung-Suk, Rela, Mohamed, Broering, Dieter, Clavien, Pierre-Alain, Kim, Jong Man , Raptis, Dimitri Aristotle , Li, Zhihao , Hong, Su young , Chen, I. , Centonze, Leonardo , Li, Zhihao , Rammohan, Ashwin , Chen, Itsuko Chih-Yi , Kirimker, Elvan Onur , Akamatsu, Nobuhisa , Shaked, Oren , Finotti, Michele , Yeow, Marcus , Nadalin, Silvio , Boehnert, Markus U , Polak, Wojciech G , Bonney, Glenn K , Samstein, Benjamin , Emond, Jean C , Testa, Giuliano , Olthoff, Kim M , Heimbach, Julie K , Taner, Timucin , Wong, Tiffany C L , Balci, Deniz , Cattral, Mark , Sapisochin, Gonzalo , Selzner, Nazia , Jeng, Long-Bin , Joh, Jae-Won , Chen, Chao-Long , Suh, Kyung-Suk , Di Sandro, Stefano , Rela, Mohamed , Broering, Dieter , Clavien, Pierre-Alain , Akamatsu, Nobuhisa , Shaked, Oren , Boehnert, Markus , Polak, Wojciech G. , Mathur, Abhishek , Samstein, Benjamin , Emond, Jean C. , Testa, Giuliano , Heimbach, Julie K. , Taner, Timuçin , Wong, Tiffany , Hasegawa, Kiyoshi , Cattral, Mark S. , Sapisochín, Gonzalo , Selzner, Nazia , Joh, Jae‐Won , Rela, Mohamed , Bröering, Dieter C. , Clavien, Pierre‐Alain

Mayo Clinic

Liver Transplantation | January 21, 2026 | Volume: 32 | Issue: 7 | Pages: 1027-1039

10.1097/lvt.0000000000000816 | PMID 41564353 Get It

Early allograft failure (EAF) after living donor liver transplantation (LDLT) remains a clinical challenge. Existing prediction models developed for deceased donor transplantation poorly apply to LDLT due to distinct surgical and physiological factors. This study identifies clinical determinants of EAF and develops an LDLT-specific prediction model. We conducted a multicenter retrospective cohort study from 17 high-volume LDLT centers (January 2016–December 2020) with external validation at a tertiary center in Saudi Arabia (January 2015–December 2022). The primary outcome was EAF (graft loss or patient death ≤90 d). Multivariable mixed-effects logistic regression identified preoperative/intraoperative risk factors. The EAGLE-LDLT model was constructed using postoperative laboratory values. Performance was compared against established models (EAD, MEAF, A2ALL) using ROC analysis and decision curve analysis. The development cohort included 2944 adult LDLT recipients (67.7% male; median age 55 y; median MELD 14) with a 5.5% EAF rate. External validation included 1020 recipients (median MELD 21, 6.7% EAF). Independent risk factors for EAF were MELD (OR 1.06, 95% CI 1.04–1.08), donor BMI (OR 1.05, 95% CI 1.00–1.10), portal vein thrombosis (OR 1.73, 95% CI 1.13–2.63), and hepaticojejunostomy (OR 1.58, 95% CI 1.06–2.36). The EAGLE-LDLT model incorporating peak ALT (>468 U/L), peak INR (>1.9), and bilirubin (>3.5 mg/dL) and INR (>1.3) at POD7, demonstrated superior discrimination (AUC=0.81) compared with MEAF (AUC=0.77, p =0.004), EAD (AUC=0.67, p <0.001), and A2ALL (AUC=0.65, p <0.001). EAGLE-LDLT achieved balanced sensitivity (75.0%) and specificity (73.7%), effectively stratifying patients into high-risk (15% of patients; 40.4% EAF incidence) and low-risk groups. Preoperative and intraoperative clinical factors predict EAF in LDLT. The EAGLE-LDLT model accurately identifies LDLT recipients at the highest risk for EAF postoperatively.
Living liver donor safety: Preoperative aspects of living liver donation—Guidelines from the ILTS–iLDLT consensus conference
Patel, Madhukar , Magistri, P., Sayed, Blayne A. , Rammohan, Ashwin, Humar, Abhinav, Abbey, Susan , Badenoch, Heather, Bhangui, Pooja , Cattral, M C, Durand, F., Hibi, Taizo, Jhaveri, Kartik , Kabacam, Gokhan, Khan, Maaz , Malik, Ashish, Nadalin, S., Ng, Vicky L, Petrowsky, Henrik , Pillai, Anjana , TOKAT, YAMAN, Wong, Tiffany, Yilmaz, Sezai, Yoshizumi, T., Nl, Ascher, Broering, Dieter, Burra, Patrizia, Chen, Chao-Long, Lerut, J., Mas, Valeria R. , Taner, Timucin, Terrault, Norah, Vyas, Mary, Wiggins, Chantal, Heimbach, Julie, Ng, Vicky L. , Rela, M., Patel, Madhukar S. , Selzner, Nazia , Sayed, Blayne A , Rammohan, Ashwin , Humar, Abhinav , Abbey, Susan , Ng, Vicky L , Rela, Mohamed , Bhangui, Prashant , Selzner, Nazia , Khan, Mohammad Qasim , Magistri, Paolo , Humar, Abhinav , Cattral, Mark S. , Durand, François , Gross, Jed Adam , Hibi, Taizo , Kabaçam, Gökhan , Malik, Ashish , Nadalin, S., Reddy, Mettu Srinivas , Wong, Tiffany, Yilmaz, Sezai , Yoshizumi, Tomoharu , Bröering, Dieter C. , Burra, Patrizia , Hirschfield, Gideon M. , Taner, Timuçin , Terrault, Norah A. , Heimbach, Julie K. , Rela, Mohamed , Bhangui, Prashant

Mayo Clinic

Liver Transplantation | January 9, 2026 | Volume: 32 | Issue: 7 | Pages: 1049-1065

10.1097/lvt.0000000000000798 | PMID 41511461 Get It

Living donor liver transplantation (LDLT) is an established therapy with curative intent for pediatric and adult patients with acute liver failure and end-stage liver disease. Donor safety remains paramount and commences during preoperative evaluation and assessment. Given the importance of the topic, the International Liver Transplantation Society and International Living Donor Liver Transplantation Group consensus conference on Living Liver Donor Safety was convened in March 2025 (Toronto, Canada). Recommendations were based on the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system for assessment of recommendations, and the Danish model of consensus was followed. This report presents 28 recommendations from the working group focused on addressing clinically relevant questions related to the preoperative aspects of living donor safety including assessment of donor acceptability (age, body mass index and hepatic steatosis; medical conditions and contraindications), medical and surgical workup (liver function and procoagulant workup; anatomical considerations and safe remnant), and psychosocial evaluation (timing and team; underlying conditions; non-directed, paired, and anonymous directed donors; urgent living donor workups for acute liver failure).
Living liver donor safety: Intraoperative considerations in living liver donation—Guidelines from the ILTS–iLDLT group consensus conference 2025
Bhangui, Prashant , Hakeem, Abdul Rahman , Maira, Tommaso Di , Rammohan, Ashwin, Sayed, Blayne A. , Soejima, Yuji , Shingina, Alexandra , Cheah, Yee Lee , McCluskey, Stuart, Spiro, Michael , Ganesh, Swaytha , Rajalingam, Rajesh , Gupta, Subash , Findlay, James Y. , Chieh, Alfred Kow Wei, Sakamoto, Seisuko, Xia, Qiang, Kim, Ki-Hun , Polak, W., Soin, A G, Pomposelli, James J. , Vyas, Mary, Wiggins, Chantal, Mas, Valeria, Taner, Timucin, Broering, Dieter, Chen, Chao-Leng, Burra, Patrizia, Ascher, N. L., Lerut, Jan, Rela, Mohamed, Selzner, Nazia, Balci, Deniz, Olthoff, Kim M. , Polak, Wojciech G. , Hakeem, Abdul , Rammohan, Ashwin , Sayed, Blayne A , McCluskey, Stuart , Findlay, James, Sakamoto, Seisuko , Xia, Qiang , Polak, Wojciech G , Sapisochin, Gonzalo , Pomposelli, James , Selzner, Nazia , Balci, Deniz , Bhangui, Prashant , Di Maira, Tommaso , Gupta, Amar C. , Xia, Qiang , Sapisochín, Gonzalo , Soin, Arvinder S., Taner, Timuçin , Bröering, Dieter C. , Terrault, Norah A. , Burra, Patrizia , Hirschfield, Gideon M. , Lerut, Jan , Rela, Mohamed , Heimbach, Julie K. , Selzner, Nazia

Mayo Clinic

Liver Transplantation | January 5, 2026 | Volume: 32 | Issue: 4 | Pages: 592-608

10.1097/lvt.0000000000000800 | PMID 41490582 Get It

The success of living donor liver transplantation (LDLT) has bridged the growing gap between organ demand and availability in patients with liver failure or liver cancer. Safety of the living liver donor (LLD) is paramount, and astute intraoperative management plays a critical role in ensuring optimal outcomes for them. Given that intraoperative surgical and anesthesia practices vary widely across centers, the International Liver Transplantation Society (ILTS) and the International Living Donor Liver Transplantation Group (iLDLT Group) convened a global consensus conference in Toronto in March 2025 to develop guidelines for intraoperative management of the LLD. This manuscript details the recommendations on intraoperative considerations for the safety of LLD developed by Working Group II of the Consensus Scientific Committee, using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system for assessment of recommendations, and the Danish model of consensus. Working Group II focused on intraoperative monitoring, fluid and ventilation strategies, surgical techniques for vascular and biliary division, surgeon and center-specific experience, and intraoperative crises planning. These guidelines aim to support both established and emerging LDLT teams to ensure high-quality and safe intraoperative care for the LLD.
Living liver donor safety: Early postoperative considerations of living liver donation guidelines from the ILTS-iLDLTG consensus conference
Sayed, Blayne Amir, Tejedor, Marta , Kathirvel, Manikandan , Bhangui, Prashant , Ghanekar, Anand, Kasahara, Mureo , Scatton, Olivier, Ghobrial, Mark, Klair, Tarunjeet , Rajakumar, Akila , Bezinover, Dimitri , Bittermann, Therese , Don, C, Luzzi, Carla , Tsien, Cynthia , Egawa, Hiroto , Ascher, Nancy L. , Bröering, Dieter C. , Chen, Chao‐Long , Lerut, Jan , Mas, Valeria R. , Taner, Timuçin , Vyas, Mary, Wiggins, Chantal, Olthoff, Kim M. , Rela, M, Selzner, Nazia, Sayed, Blayne A. , Bhangui, Prashant , Rammohan, Ashwin , Selzner, Nazia , Tejedor, Marta , Sayed, Blayne A , Chadha, Ryan , Ivanics, Tommy , Kim, Dong‐Sik , Scatton, Olivier , Ghobrial, Mark, Sudhindran, S , Benedetto, Fabrizio Di , Burra, Patrizia , Hirschfield, Gideon M. , Terrault, Norah A. , Wiggins, Chantal, Fung, John J. , Heimbach, Julie K. , Selzner, Nazia

Mayo Clinic

Liver Transplantation | December 18, 2025 | Volume: 32 | Issue: 6 | Pages: 913-924

10.1097/lvt.0000000000000791 | PMID 41410428 Get It

Living donor liver transplantation (LDLT) is a life-saving procedure for patients with end-stage liver disease. As its use expands worldwide, ensuring the safety and well-being of live liver donors (LLD) is of paramount importance. Published evidence on early postoperative complications after living donor hepatectomy—those occurring within 90 days of surgery—is limited, and standardized postoperative care protocols are lacking. The International Liver Transplantation Society (ILTS) and the International Living Donor Liver Transplantation Group (iLDLT Group) convened a consensus conference in Toronto in March 2025 to develop guidelines for the safe care of the LLDs. This manuscript details the recommendations on early postoperative considerations for the safety of LLDs developed by Working Group III (WGIII) of the Consensus Scientific Committee, using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system for assessment of recommendations, and the Danish model of consensus. WGIII addressed four key areas: (1) standardized postoperative care, (2) early biliary complications, (3) early postoperative liver dysfunction, and (4) early postdischarge follow-up. This report emphasizes the need for vigilant postoperative monitoring in specialized units, with access to experienced providers and defined clinical pathways. Structured clinical and psychosocial follow-up protocols, perioperative prophylaxis for surgical site infections and venous thromboembolism, and management of early biliary and vascular complications are discussed. These may help standardize care, reduce complications and improve short-term outcomes in LLDs.
Long-term considerations following living liver donation—Guidelines from the 2025 ILTS-iLDLT consensus conference on living liver donor safety
Sayed, Blayne A. , Jung, Dong-Hwan, Watt, Kymberly D. , Maluf, Daniel G. , Zhu, Zhi‐Jun , Eghtesad, Bijan , Minnee, Robert C. , James, Paul M., Man, Nancy Kwan, Liapakis, AnnMarie , Fipps, David C. , Taner, Timuçin , Wiggins, Chantal, Ascher, Nancy L. , Mas, Valeria, Chen, Chao‐Long, Vyas, Mary, Suk-Suh, Kyung, Broering, Dieter , Lerut, Jan , Olthoff, Kim M. , Rela, Mohamed, Fipps, David C , Sayed, Blayne A , Chan, Albert C Y , Rammohan, Ashwin , Shankar, Sadhana , Syn, Nicholas L. X. , Mathew, Johns Shaji , Bhangui, Prashant , Jung, Dong‐Hwan , Pomfret, Elizabeth , Roberts, John P. , Selzner, Markus , Chan, Albert , Chaudhary, Abhideep , Eguchi, Susumu , James, Paul, Goldaracena, Nicolás , Kodali, Sudha , Kim, Jong Man , Wiggins, Chantal, Terrault, Norah A. , Burra, Patrizia , Hirschfield, Gideon M. , Heimbach, Julie K. , Selzner, Nazia , Rela, Mohamed

Mayo Clinic

Liver Transplantation | December 18, 2025 | Volume: 32 | Issue: 8 | Pages: 1194-1209

10.1097/lvt.0000000000000790 | PMID 41410423 Get It

Living liver donation is a critical component for addressing organ shortage and improving outcomes for patients with end-stage liver disease. As the prevalence of living donor liver transplantation (LDLT) increases worldwide, understanding and optimizing long-term donor health is paramount. The 2025 International Liver Transplantation Society and International Living Donor Liver Transplantation Society (ILTS-iLDLT) Consensus Conference convened experts in the field of liver transplantation to establish evidence-based guidelines focused on the long-term medical, psychological, and social considerations following living liver donation. The aim of this working group was to integrate current evidence and expert consensus on donor follow-up protocols, risk assessment, and management strategies to promote long-term donor health, quality of life, and living liver donor programs globally to safeguard the welfare of this unique population.
Label‐Free Single‐Molecule Immunoassay
Chen, Chao , Zhou, Shuang , Chemerkouh, Mohammad Javad Haji Najafi , Snozek, Christine L.H. , Jiang, Jiapei, Braswell, Brandyn, Chen, C.-H. , Wang, Shaopeng , Chen, Chao , Zhou, Xiaoyan , Ma, Guangzhong , Yang, Eric H. , Wan, Zijian , Zhou, Xinyu , Wang, Shaopeng

Mayo Clinic

Advanced Science | June 20, 2025 | Volume: 12 | Issue: 31 | Pages: No page available

10.1002/advs.202505207 | PMID 40538199 Get It

Abstract Single‐molecule immunoassay is a reliable technique for the detection and quantification of low‐abundance blood biomarkers, which are essential for early disease diagnosis and biomedical research. However, current single‐molecule methods predominantly rely on endpoint detection and necessitate signal amplification via labeling, which brings a variety of unwanted effects, like matrix effect and autofluorescence interference. This study introduces a real‐time mass imaging‐based label‐free single‐molecule immunoassay (LFSMiA). Featuring plasmonic scattering microscopy‐based mass imaging, a 2‐step sandwich assay format enables background reduction, minimization of matrix effect by dynamic tracking of single binding events, and fully leveraging real‐time data for improved measurement precision through a Bayesian Gaussian process model, the LFSMiA enables ultra‐sensitive and direct protein detection at the single‐molecule level in neat blood sample matrices. LFSMiA measurement is demonstrated for interleukin‐6 and prostate‐specific antigen in buffer, undiluted serum, and whole blood with sub‐femtomolar detection limits and eight logs of dynamic ranges. Moreover, comparable performance is achieved with an inexpensive miniaturized setup. To show its translational potential to clinical settings and point‐of‐care diagnostics, N‐terminal pro‐B‐type natriuretic peptide is examined in patient whole blood samples using the LFSMiA and results in a strong linear correlation (r > 0.99) with standard clinical lab results.
Multi-center evaluation of radiomics and deep learning to stratify malignancy risk of IPMNs
Bejar, Andrea Mia, Gonzalez, Maria , Hong, Ziliang , Aktas, Halil Ertugrul , Zhang, Zheyuan , Pan, Hongyi, Jozwiak, Zeynep Sue, Bol, Fergan , Zhao, Lili , Kartal, Gulbiz Dagoglu, Agarunov, Emil, Bruno, Marco J. , Huang, Chenchang, Gonda, Tamas A. , Bolan, Candice W. , Keswani, Rajesh N. , Tiwari, Pallavi , Bolan, Candice, Gonzalez, María Jaramillo, Durak, Görkem , Keleş, Elif , Pan, Hongyi , Jozwiak, Zeynep Sue, Chen, Chao , Spampinato, Concetto , Medetalibeyoğlu, Alpay , Ertürk, Şükrü Mehmet , Velichko, Yury , Xu, Ziyue , Jambawalikar, Sachin , Schoots, Ivo G. , Huang, Chenchang, Miller, Frank H. , Wallace, Michael B. , Tiwari, Pallavi , Bağcı, Ulaş

Mayo Clinic

No container title available | May 30, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6622868/v1 | PMID 40502758 Get It

Abstract Distinguishing high-risk intraductal papillary mucinous neoplasms (IPMNs), pancreatic cysts requiring surgery, from low-risk lesions remains a clinical challenge, often resulting in unnecessary procedures due to limited specificity of current methods. While radiomics and deep learning (DL) have been explored for pancreatic cancer, cyst-level malignancy risk stratification of IPMNs remains untapped. We conducted a multi-institutional study (seven centers, 359 T2W MRI images) to assess the feasibility of AI for predicting IPMN dysplasia grade using cyst-level image features. We developed and compared 2D and 3D radiomics-only, deep learning (DL)-only, and radiomics-DL fusion models, using expert radiologist scoring as a baseline reference. Model performance was evaluated using held-out test data. The radiomics-DL fusion model showed the highest discriminatory ability on the test set (AUC 0.692), outperforming the radiomics-only model (AUC 0.665). Expert accuracy varied widely (37.4%-66.7%). The fusion model integrating deep learning and radiomics features from routine T2W MRI (AUC: 0.692) demonstrates potential for objective, cyst-level risk stratification of IPMNs in a multi-center cohort, outperforming both radiomics-only models and expert radiologists. While performance requires improvement for standalone clinical use, this approach offers a scalable, non-invasive method to potentially improve diagnostic accuracy and reduce unnecessary surgical interventions.
Validation of a Pretransplant Risk Prediction Model for Early Allograft Dysfunction After Living-donor Liver Transplantation
Gunasekaran, Vasanthakumar , Chen, I. , Marquez, Kris Ann Hervera , Hsu, Shih-Chao, Akamatsu, Nobuhisa , Shaked, Oren , Genedy, Lara, Yebyo, Henock G. , Dutkowski, Philipp , Boehnert, Markus , Mathur, Abhishek , Emond, Jean C. , Testa, Giuliano , Olthoff, Kim M. , Rosen, Charles B. , Taner, Timuçin , Wong, Tiffany , Lo, Chung‐Mau, Cattral, Mark S. , Sapisochin, Gonzalo, Jeng, Long‐Bin , Chen, Chao‐Long , Rela, Mohamed , Bröering, Dieter C. , Clavien, Pierre‐Alain , Li, Zhihao , Yeow, Marcus, Hsu, Shih-Chao , Li, Zhihao , Akamatsu, Nobuhisa , Wong, Tiffany C L , Li, Zhihao, Raptis, Dimitri , Rammohan, Ashwin , Hong, Su young , Kim, Jong Man , Kirimker, Elvan Onur , Finotti, Michele , Yeow, Marcus , Braun, Julia , Nadalin, Silvio , Polak, Wojciech G. , Bonney, Glenn Kunnath , Samstein, Benjamin , Heimbach, Julie K. , Hasegawa, Kiyoshi , Balci, Deniz , Sapisochín, Gonzalo , Selzner, Nazia , Joh, Jae-Won , Suh, Kyung-Suk

Mayo Clinic

Transplantation | January 28, 2025 | Volume: 109 | Issue: 8 | Pages: 1383-1392

10.1097/tp.0000000000005331 | PMID 39883022 Get It

Background. Early allograft dysfunction (EAD) affects outcomes in liver transplantation (LT). Existing risk models developed for deceased-donor LT depend on posttransplant factors and fall short in living-donor LT (LDLT), where pretransplant evaluations are crucial for preventing EAD and justifying the donor’s risks. Methods. This retrospective study analyzed data from 2944 adult patients who underwent LDLT at 17 centers between 2016 and 2020. We developed a logistic regression model to predict EAD based on this development cohort. We used data from 1020 patients at the King Faisal Transplant Center for external validation. Results. In the development cohort, 321 patients (10.9%) experienced EAD. These patients had poorer health status, more liver decompensation, and higher requirements of hospitalization than those without EAD. Multivariable logistic regression identified independent pretransplant predictors of EAD: laboratory Model for End-Stage Liver Disease score (odds ratio [OR], 1.08; 95% confidence interval [CI], 1.06-1.09), the necessity for hospitalization at the time of transplant (OR, 2.58; 95% CI, 2.00-3.30), and graft weight in kilogram (OR, 0.27; 95% CI, 0.17-0.45). Using these predictors, we developed the model for EAD after LDLT, which demonstrated strong discriminative ability in the development cohort with an area under the curve (AUC) of 0.71 (95% CI, 0.68-0.74). The model maintained high discrimination during internal validation (AUC, 0.70; 95% CI, 0.67-0.73) and showed a modest reduction in discriminative power in external validation (AUC, 0.65; 95% CI, 0.61-0.68). Conclusions. EAD post-LDLT is influenced by the recipient’s pretransplant health condition and the graft weight. Integrating the model for EAD after LDLT into the pretransplant process of pairing donors and recipients can enhance the safety and efficacy of LDLT.
Microfluidic Digital Immunoassay for Point-of-Care Detection of NT-proBNP from Whole Blood
Chen, C.-H. , Zhou, Xiaoyan , Snozek, Christine L.H. , Chen, Chao , Zhou, Xiaoyan , Snozek, Christine Lh, Wang, Shaopeng , Porter, Ryan, Yang, Eric H. , Wang, Shaopeng

Mayo Clinic

Analytical Chemistry | June 15, 2024 | Volume: 96 | Issue: 26 | Pages: 10569-10576

10.1021/acs.analchem.4c01046 | PMID 38877973 Get It

Label-free Single-molecule Immunoassay
Zhou, Xiaoyan , Chemerkouh, Mohammad Javad Haji Najafi , Snozek, Christine L.H. , Braswell, Brandyn, Wan, Zijian, Chen, Chao , Ma, Guangzhong , Yang, Eric H. , Wan, Zijian , Wang, Shaopeng

Mayo Clinic

No container title available | December 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.26434/chemrxiv-2023-vnxgr Get It

Single-molecule immunoassay is a reliable technique for the detection and quantification of low-abundance blood biomarkers, which are essential for early disease diagnosis and biomedical research. However, current single-molecule methods all require signal amplification via labelling, which brings a variety of unwanted consequences, such as matrix effects and autofluorescence interference. Here, we introduce a real-time mass imaging-based label-free single-molecule immunoassay (LFSM-immunoassay). Featuring plasmonic scattering microscopy-based real-time mass imaging, a 2-step sandwich assay format-enabled background reduction, and minimization of matrix effects by dynamic tracking of single binding events, the LFSM-immunoassay enables ultra-sensitive and direct protein detection at the single-molecule level in neat blood sample matrices. We demonstrated that the LFSM-immunoassay can measure sub-femtomolar levels of interleukin-6 and prostate-specific antigen in whole blood with 8 log dynamic range. To show its translational potential to clinical settings, we measured NT-proBNP (N-terminal pro-brain natriuretic peptide) in 28 patient serum samples using a 20 minute LFSM-immunoassay, and the results show a strong linear correlation (r > 0.99) with clinical lab reported values.